AbbVie’s Skyrizi Wins EU Nod for Ulcerative Colitis, Helps to Weather Humira Patent Cliff

Friday’s European Commission approval is a boost to AbbVie as the company looks to lean on its immunology assets, including Skyrizi, to soften the blow of Humira’s loss of exclusivity.